4.6 Article

Donor source and post-transplantation cyclophosphamide influence outcome in allogeneic stem cell transplantation for GATA2 deficiency

Related references

Note: Only part of the references are listed.
Article Oncology

Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia

John C. Molina et al.

Summary: Chronic myelomonocytic leukemia (CMML) is a common myelodysplastic syndrome/myeloproliferative disorder in the elderly, but rare in adolescents. This case report describes an adolescent with monosomy 7 CMML presenting with central diabetes insipidus (DI), treated with venetoclax and decitabine as a bridge to hematopoietic stem cell transplantation (HSCT).

PEDIATRIC BLOOD & CANCER (2021)

Article Hematology

Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen

Mark Parta et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)

Editorial Material Hematology

HSCT for GATA2 deficiency across the pond

Dennis Hickstein

BLOOD (2018)

Article Hematology

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency

Jennifer Grossman et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)

Article Multidisciplinary Sciences

Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches

Agnieszka Czechowicz et al.

SCIENCE (2007)